ReViral
Latest round
- Series C
Last raised
- Aug 2020
Total raised
- $125M
Investors
- 8
About ReViral
ReViral Ltd.ReViral Ltd. was founded in 2011 in the UK, specializing in antiviral therapeutics. In April 2022, Pfizer Inc.ReViral Ltd. specializes in developing antiviral therapies, particularly targeting respiratory syncytial virus (RSV).In 2022, ReViral Ltd.Following the recent acquisition by Pfizer Inc. in April 2022, ReViral Ltd. The company aims to accelerate the launch of new product offerings and expand its market presence in the global antiviral therapeutics landscape.
Who invested in ReViral
8 investors across 3 rounds
See all investors in ReViral
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ReViral
Who invested in ReViral?
ReViral has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ReViral raised?
ReViral has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ReViral last raise money?
ReViral's most recent round on record is a Series C, in Aug 2020.
What does ReViral do?
ReViral is a pharmaceuticals company.
Where is ReViral headquartered?
ReViral is headquartered in UK.
Which VCs invest in companies like ReViral?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back pharmaceuticals companies at ReViral's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like ReViral? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.